(Q52207128)

27 April 2018

title

Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost. (English)

1 reference

27 April 2018

1 reference

1 reference

metastatic breast cancer

1 reference

3

Tannock IF

1 reference

27 April 2018

author name string

McLachlan SA

series ordinal

1

1 reference

27 April 2018

Pintilie M

series ordinal

2

1 reference

27 April 2018

language of work or name

English

0 references

publication date

1 April 1999

1 reference

27 April 2018

Breast Cancer Research and Treatment

published in

1 reference

27 April 2018

volume

54

1 reference

27 April 2018

issue

3

1 reference

27 April 2018

page(s)

213-223

1 reference

27 April 2018

https://scigraph.springernature.com/pub.10.1023/a:1006123721205

exact match

0 references

cites work

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Chemotherapy of advanced breast cancer: outcome and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

A validation study of the domains of the core EORTC quality of life questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Measurement of health state utilities for economic appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Response-shift bias: a challenge to the assessment of patients' quality of life in cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Eliciting preferences for alternative cancer drug treatments. The influence of framing, medium, and rater variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Advanced breast cancer and its prevention by screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

The cost of breast cancer recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Advanced breast cancer: use of resources and cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

7 January 2021

Fatigue in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

7 January 2021

The "utility" of the Time Trade-Off method in cancer patients: feasibility and proportional Trade-Off

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

7 January 2021

A comparison of time trade-off and quality of life measures in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

7 January 2021

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006123721205

7 January 2021

Identifiers

DOI

10.1023/A:1006123721205

1 reference

27 April 2018

Dimensions Publication ID

0 references

1 reference

27 April 2018